Copyright
©2013 Baishideng. All rights reserved.
Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders
Marie-Christine Kyrtsonis, Dimitrios Maltezas, Efstathios Koulieris, Tatiana Tzenou, Haematology Section of 1st Department of Propaedeutic Internal Medicine, Athens Medical School, Laikon University Hospital, 11527 Athens, Greece
Stephen J Harding, The Binding Site Group Ltd., Birmingham B15 1QT, United Kingdom
Author contributions: Kyrtsonis MC and Harding SJ designed research; Kyrtsonis MC, Maltezas D, Koulieris E, Tzenou T and Harding SJ wrote the paper.
Correspondence to: Marie-Christine Kyrtsonis, MD, PhD, Assistant Professor of Hematology, Haematology Section of 1st Department of Propaedeutic Internal Medicine, Athens Medical School, Laikon University Hospital, Agiou Thoma 17, 11527 Athens, Greece. mck@ath.forthnet.gr
Telephone: +30-210-7462183 Fax: +30-210-7462183
Received: November 15, 2012
Revised: March 29, 2013
Accepted: April 10, 2013
Published online: May 6, 2013
Revised: March 29, 2013
Accepted: April 10, 2013
Published online: May 6, 2013
Core Tip
Core tip: Recently manufactured assays allow the quantification of serum immunoglobulin (Ig) free light chain (sFLC) or of κ or λ restricted heavy Ig chain separately (HLC). These measurements, or the calculation of their corresponding ratios, were shown useful for routine clinical practice in Hematology. sFLC measurements added important prognostic information for monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), amyloid light-chain (AL) amyloidosis, Waldenstrom’s macroglobulinemia and chronic lymphocytic leukemia while they contributed to accurate follow-up of MGUS, MM and AL amyloidosis patients. HLC measurements are more recent and mainly concern MM in which they constituted a prognostic marker.